Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. announced a license agreement under which Astellas gains rights to utilize the intravitreal retinotropic R100* vector invented by 4DMT for one genetic target implicated in rare monogenic ophthalmic disease, with options to add up to two additional targets implicated in rare monogenic ophthalmic diseases after paying additional option exercise fees.
